奥美沙坦酯治疗原发性轻-中度高血压的疗效和安全性

The curative effect and safety of olmesartan cilexetil in patients with mild to moderate primary hypertension

目的评价奥美沙坦酯治疗轻中度原发性高血压的疗效和安全性。方法121例原发性轻中度高血压的患者双盲随机分为奥美沙坦酯20．mg（n=60）和缬沙坦80mg（n=61）组，治疗8周，观察两组治疗前后的血压、心电图、血生化及尿实验室检查的变化。结果治疗8周，奥美沙坦酯与缬沙坦比较，收缩压与舒张压降低程度差异均有统计学意义，收缩压（120．54±12．78）mmHg：（128．32±10．01）mmHg；舒张压：（73．27±4．01）mmHg：（79．65±4．89）mmHg，奥美沙坦酯能有效降压，应用奥美沙坦酯20mg每天口服1次药物作用基本可维持24h。药物降低SBP与DBP的谷峰比值大于50％，两组药物不良反应发生率分别为2例和5例。结论奥美沙坦酯治疗原发性轻、中度高血压具有满意的疗效和较高的安全性。

Objective To study the curative effect and the safety of olmesartan medoxomil in patients with mild to moderate primary hypertension. Methods 121 patients with mild to moderate essential hypertension were randomized into two groups ： olmesartan group （ n = 60） , received olmesartan 20rag/day and valsartan group （ n = 61 ）, received valsartan 8mg/day. Before and after the 8 weeks treatment, blood pressurem, ECG, blood and urinary laboratory exanination were observed in EH cases. Results After 8 weeks, Compared to valsartan group, the olmesartan group showed significantly erduction in both systolic blood pressure [ （ 120.54±12.78 ） mm Hg ： （ 128. 32±10.01 ） mm Hg] and diastolic blood pressure[ （73.27±4.01 ） mm Hg ： （79.65±4. 89） mm Hg]. In terms of the 24 h ABPM,olmesartan monotherapy exhibited a sustained 24h BP reduction profile with the trough-to-peak ratios more than 50%. The side effect in olmesartan group was 2 cases, and 5 cases in valsartan group. Conclusion Candesartan cilexetil can be used in the treatment of patients with mild and moderate essential hypertension effectively and safely.